Bicara Therapeutics (BCAX) Expected to Announce Earnings on Tuesday

Key Points

• Bicara Therapeutics is scheduled to announce its Q2 2025 earnings on August 12th, with expectations of posting a loss of ($0.54) per share.
• The stock is currently trading down 0.1% at $11.11, with analysts giving it a consensus rating of "Moderate Buy" and a target price of $31.86.
• AQR Capital Management has recently acquired a new stake in Bicara Therapeutics, purchasing 19,034 shares valued at approximately $248,000.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Bicara Therapeutics to post earnings of ($0.54) per share for the quarter.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.53 on Thursday, hitting $9.91. The company had a trading volume of 12,271 shares, compared to its average volume of 617,515. The firm has a 50 day moving average of $10.39 and a two-hundred day moving average of $12.00. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $28.09.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BCAX. HC Wainwright decreased their price objective on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Wedbush reiterated an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Wells Fargo & Company upgraded shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target for the company in a report on Friday, May 23rd. Finally, Wall Street Zen cut shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.86.

Institutional Trading of Bicara Therapeutics

An institutional investor recently bought a new position in Bicara Therapeutics stock. AQR Capital Management LLC acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 19,034 shares of the company's stock, valued at approximately $248,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.